Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesPredictors of variability in urinary incontinence and overactive bladder symptoms
Neurourology and Urodynamics, 08/26/09
Stewart WF et al. – Inter–individual and intra–individual occurrences of urgency and UI symptoms are highly variable in the general population. Use of established predictors to select individuals with less variability in symptoms may help to reduce placebo rates in clinical trials.
Related Articles
Fesoterodine for the Treatment of Overactive Bladder
Annals of Pharmacotherapy, 11/18/09
Relevance Score: 69%
The importance of bladder wall thickness in the assessment of overactive bladder
Current Bladder Dysfunction Reports, 11/13/09
Relevance Score: 69%
The relationship between sleep apnea and overactive bladder
Current Urology Reports, 11/17/09
Relevance Score: 68%
Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study
BJU International, 10/13/09
Relevance Score: 68%
Frequently asked questions in the evaluation and management of overactive bladder
The Journal of Family Practice, 11/02/09
Relevance Score: 67%
Today in Bladder...keeping you current
Receive free subspecialty "5-minute updates" via email
Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial
Anti-Cancer Drugs, 12/09/09
Randomized, Double-blind, Placebo-controlled Trial of Flexible-dose Fesoterodine in Subjects With Overactive Bladder
Urology, 12/09/09
Current status of robot-assisted radical cystectomy
Current Opinion in Urology, 12/09/09
Today in Voiding Dys/Incontinence...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized, Double-blind, Placebo-controlled Trial of Flexible-dose Fesoterodine in Subjects With Overactive Bladder
Urology, 12/09/09
Lower urinary tract symptoms, obesity and the metabolic syndrome
Current Opinion in Urology, 12/09/09
Does the combination of an [alpha]1-adrenergic antagonist with a 5[alpha]-reductase inhibitor improve urinary symptoms more than either monotherapy
Current Opinion in Urology, 12/09/09
Article Search
Sponsor